Skip to content
Subscriber Only

Amgen's Just-Approved Migraine Drug Will Cost $6,900 a Year

Chili Peppers Seen Helping 36 Million Migraine Sufferers

Photographer: Bloomberg/Bloomberg

Updated on

Amgen Inc. will charge a lower-than-expected $6,900 a year for a novel migraine treatment that investors hope will become the biotechnology giant’s next blockbuster.

The Food and Drug Administration approved the drug, which will be marketed under the brand name Aimovig, on Thursday. It’s part of a class of therapies known as a CGRP-inhibitors that offer new options to patients who get the recurrent, painful headaches.